Pathologic complete response and overall survival in breast cancer subtypes in stage III inflammatory breast cancer
Pathologic complete response and overall survival in breast cancer subtypes in stage III inflammatory breast cancer
复制标题
DOI：
10.1007/s10549-019-05219-7
复制
发表时间：
2019-07-01
影响因子：
3.8
通讯作者：
de Wilt, Johannes H. W.
中科院分区：
文献类型：
--
作者：
van Uden, Dominique J. P.;van Maaren, Marissa C.;de Wilt, Johannes H. W.
目的分析III期炎性乳腺癌（IBC）中基于激素受体（HR）和人表皮生长因子受体2（HER2）的分子亚型对肿瘤特征、治疗、新辅助化疗（NACT）病理反应和总生存（OS）的影响。方法将2006年至2015年在荷兰诊断的III期IBC患者分为四种乳腺癌亚型：HR+/HER2-、 HR+/HER2+、HR-/HER2+ 和 HR-/HER2-。比较患者、肿瘤和治疗相关的特征。对于 NACT，比较亚组之间的病理完全缓解 (pCR)。采用Kaplan-Meier曲线和时序检验比较各亚型的OS。结果1061例III期IBC患者分为HR+/HER2-(N=453, 42.7%)、HR-/HER2-(N=258, 24.3%)、HR-/HER2+(N=180,17.0%)和HR-/HER2-(N=180,17.0%)亚型。 HR+/HER2+(N=170,16.0%)。总共有 679 名患者 (85.0%) 接受了 NACT。在 HR-/HER2+ 肿瘤中，pCR 率最高（43%，（p
PurposeTo analyze the influence of hormone receptors (HR) and Human Epidermal growth factor Receptor-2 (HER2)-based molecular subtypes in stage III inflammatory breast cancer (IBC) on tumor characteristics, treatment, pathologic response to neoadjuvant chemotherapy (NACT), and overall survival (OS).MethodsPatients with stage III IBC, diagnosed in the Netherlands between 2006 and 2015, were classified into four breast cancer subtypes: HR+/HER2-, HR+/HER2+, HR-/HER2+, and HR-/HER2-. Patient-, tumor- and treatment-related characteristics were compared. In case of NACT, pathologic complete response (pCR) was compared between subgroups. OS of the subtypes was compared using Kaplan-Meier curves and the log-rank test.Results1061 patients with stage III IBC were grouped into subtypes: HR+/HER2-(N=453, 42.7%), HR-/HER2-(N=258, 24.3%), HR-/HER2+(N=180,17.0%), and HR+/HER2+(N=170,16.0%). In total, 679 patients (85.0%) received NACT. In HR-/HER2+tumors, pCR rate was highest (43%, (p